Syndax Pharmaceuticals SNDX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's total liabilities & equity?
- Syndax Pharmaceuticals (SNDX) reported total liabilities & equity of $472.67M in Q1 2026.
- How has Syndax Pharmaceuticals's total liabilities & equity changed year-over-year?
- Syndax Pharmaceuticals's total liabilities & equity decreased by 26.2% year-over-year, from $640.71M to $472.67M.
- What is the long-term trend for Syndax Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total liabilities & equity has grown at a 12.0% compound annual growth rate (CAGR), from $300.61M to $529.71M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.